» Articles » PMID: 23161899

Oral Administration of GLPG0259, an Inhibitor of MAPKAPK5, a New Target for the Treatment of Rheumatoid Arthritis: a Phase II, Randomised, Double-blind, Placebo-controlled, Multicentre Trial

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2012 Nov 20
PMID 23161899
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mitogen-activated protein (MAP) kinases are key regulators of cytokine production, and are therefore potential targets for treatment of rheumatoid arthritis (RA).

Objective: This two-part phase II study investigated the efficacy and safety of a once-daily 50 mg GLPG0259 (an inhibitor of MAP kinase-activated protein kinase 5) dose vs placebo (part A). An interim analysis after part A would determine whether the dose-finding part (part B) would be performed.

Methods: In part A, eligible methotrexate (MTX)-refractory patients with RA were randomised to receive either a once-daily 50 mg dose of GLPG0259 or placebo, in addition to a stable dose of MTX, for 12 weeks. The primary efficacy end point was the percentage of patients achieving an American College of Rheumatology 20% improvement (ACR20) response after 12 weeks.

Results: The interim analysis showed no difference between the percentage of subjects achieving the primary efficacy variable of ACR20 or the secondary efficacy variables (ACR50, ACR70 and Disease Activity Score 28) at week 12 in the GLPG0259-treated (n=19) and placebo-treated (n=11) groups. Owing to lack of efficacy, the study was terminated, and part B was not initiated.

Conclusions: This innovative study design quickly provided conclusive results on the lack of efficacy of GLPG0259 in patients with RA.

Citing Articles

The Role of Oxidative Stress in Intervertebral Disc Degeneration.

Cao G, Yang S, Cao J, Tan Z, Wu L, Dong F Oxid Med Cell Longev. 2022; 2022:2166817.

PMID: 35069969 PMC: 8769842. DOI: 10.1155/2022/2166817.


TLK1-mediated MK5-S354 phosphorylation drives prostate cancer cell motility and may signify distinct pathologies.

Khalil M, Singh V, King J, De Benedetti A Mol Oncol. 2022; 16(13):2537-2557.

PMID: 35064619 PMC: 9251878. DOI: 10.1002/1878-0261.13183.


The essential role of PRAK in tumor metastasis and its therapeutic potential.

Wang Y, Wang W, Wu H, Zhou Y, Qin X, Wang Y Nat Commun. 2021; 12(1):1736.

PMID: 33741957 PMC: 7979731. DOI: 10.1038/s41467-021-21993-9.


The adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation.

El-Merahbi R, Viera J, Valdes A, Kolczynska K, Reuter S, Loffler M Genes Dev. 2020; 34(7-8):495-510.

PMID: 32139423 PMC: 7111262. DOI: 10.1101/gad.333617.119.


Genome-wide analysis of DNA methylation profile identifies differentially methylated loci associated with human intervertebral disc degeneration.

Ikuno A, Akeda K, Takebayashi S, Shimaoka M, Okumura K, Sudo A PLoS One. 2019; 14(9):e0222188.

PMID: 31513634 PMC: 6742346. DOI: 10.1371/journal.pone.0222188.